Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers

Breast Cancer Research

Table 3 Odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer comparing plasma prolactin ≥ 11 versus < 11 ng/mL by tumor expression of prolactin-related markers among postmenopausal women

Tumor status	N (Cases)	Prolactin levels (ng/mL)		p-heterogeneity
Tumor status	N (Cases)	≤ 11	> 11	p-heterogeneity
All breast cancer	577	1(Ref)	1.37 (1.12, 1.67)
Prolactin receptor
Nuclear^a
Negative	406	1 (Ref)	1.32 (1.05, 1.66)	0.65
Positive	139	1 (Ref)	1.45 (1.01, 2.07)	0.65
Cytoplasmic^a
Negative	416	1 (Ref)	1.32 (1.05, 1.65)	0.60
Positive	129	1 (Ref)	1.47 (1.01, 2.14)	0.60
pSTAT5
Nuclear^a
Negative	394	1 (Ref)	1.29 (1.03, 1.63)	0.21
Positive	125	1 (Ref)	1.69 (1.16, 2.46)	0.21
Cytoplasmic^b
Negative	213	1 (Ref)	1.43 (1.07, 1.92)	0.73
Positive	306	1 (Ref)	1.34 (1.04, 1.73)	0.73
Combined nuclear/cytoplasmic
Both negative	189	1 (Ref)	1.45 (1.06, 1.97)	0.53
Both positive	101	1 (Ref)	1.78 (1.18, 2.68)
One negative/one positive	229	1 (Ref)	1.35 (1.02, 1.80)
pJAK2^b
Negative	95	1 (Ref)	1.52 (0.99, 2.33)	0.68
Positive	409	1 (Ref)	1.38 (1.10, 1.73)	0.68

Bolded values are statistically significant (p < 0.05)
Adjusted for age (continuous), age at menarche (continuous), BMI (continuous), benign breast disease (never, confirmed, unconfirmed), HT status (no, yes), and blood draw characteristics (fasting status and month of blood collection)
^aA case was considered positive if one or more cores were scored 2 or 3
^bCytoplasmic pSTAT5 and pJAK2 was scored positive if any core was scored 1 or higher

ISSN: 1465-542X